☆ 4.4 Letter

Combined CXCR3/CXCR4 measurements are of high prognostic value in chronic lymphocytic leukemia due to negative co-operativity of the receptors

HAEMATOLOGICA (2016)

Journal

HAEMATOLOGICA

Volume 101, Issue 3, Pages E99-E102

Publisher

FERRATA STORTI FOUNDATION

DOI: 10.3324/haematol.2015.133470

Keywords

CLL; microenvironment; B-cell receptor; chemokine; CXCL12

Categories

Hematology

Funding

Austrian Science Fund FWF [P 25015] Funding Source: Medline
Austrian Science Fund (FWF) [P25015, W1213] Funding Source: Austrian Science Fund (FWF)
Austrian Science Fund (FWF) [P 25015] Funding Source: researchfish

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Immunology

ACKR3 promotes CXCL12/CXCR4-mediated cell-to-cell-induced lymphoma migration through LTB4 production

Paola Antonello, Diego U. Pizzagalli, Mathilde Foglierini, Serena Melgrati, Egle Radice, Sylvia Thelen, Marcus Thelen

Summary: Chemotaxis is an essential process in tumors metastasis, and in this study, ACKR3 was found to control the migration of lymphoma cells in response to CXCL12. The interaction between LTB4 and CXCL12 enhances the migration of lymphoma cells, providing a novel mechanism for cell-to-cell-induced migration.

FRONTIERS IN IMMUNOLOGY (2023)

Add to Collection

Article Cell Biology

LPA1-mediated inhibition of CXCR4 attenuates CXCL12-induced signaling and cell migration

Jong Min Hong, Jin-Woo Lee, Dong-Seung Seen, Jae-Yeon Jeong, Won-Ki Huh

Summary: The heteromerization between CXCR4 and LPA1 has been investigated, showing its important role in cancer cells and providing insights into the regulatory mechanism of CXCR4 through heteromer formation. The findings suggest a potential therapeutic approach using combined CXCR4 and LPA1 inhibitors for cancer and inflammatory diseases associated with these receptors.

CELL COMMUNICATION AND SIGNALING (2023)

Add to Collection

Article Oncology

CXCR4 mediates leukemic cell migration and survival in the testicular microenvironment

Tessa Skroblyn, Jara J. Joedicke, Madlen Pfau, Kerstin Krueger, Jean-Pierre Bourquin, Shai Izraeli, Cornelia Eckert, Uta E. Hoepken

Summary: The study identified CXCL12-CXCR4 as the leading signaling axis for B-ALL cell migration and survival in the testicular leukemic niche. CXCR4 was found to be the only chemokine receptor robustly expressed on B-ALL cells in both diagnosis and relapse samples. Blocking CXCR4 functions showed promising results in preventing testicular infiltration and overall development of leukemia.

JOURNAL OF PATHOLOGY (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Chemokine-Directed Tumor Microenvironment Modulation in Cancer Immunotherapy

Pedro Bule, Sandra Isabel Aguiar, Frederico Aires-Da-Silva, Joana Nunes Ribeiro Dias

Summary: Chemokines play a crucial role in cancer development by influencing various processes such as angiogenesis, metastasis, and stemness. The chemokine network has emerged as a potential target for immunotherapy and may have therapeutic effects when used alone or in combination with other treatments.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2021)

Add to Collection

Article Oncology

Prognostic Impact of CXCR7 and CXCL12 Expression in Patients with Esophageal Adenocarcinoma

Masakazu Goto, Yukiko Shibahara, Cristina Baciu, Frances Allison, Jonathan C. Yeung, Gail E. Darling, Mingyao Liu

Summary: This study found that high expression of CXCR7 is associated with poor prognosis in patients with esophageal adenocarcinoma, and the combination of high expression of CXCR7 and CXCL12 has a stronger association with prognosis. Additionally, high expression of both CXCR7 and CXCL12 was identified as an independent prognostic factor for overall and disease-free survival in patients with esophageal adenocarcinoma. Further research with larger sample sizes is warranted to explore the potential of this biomarker.

ANNALS OF SURGICAL ONCOLOGY (2021)

Add to Collection

Review Oncology

The biological role of the CXCL12/CXCR4 axis in esophageal squamous cell carcinoma

Xianxian Wu, Hongdian Zhang, Zhilin Sui, Yang Wang, Zhentao Yu

Summary: Esophageal squamous cell carcinoma is the main type of esophageal cancer, where abnormal expression of CXCL12 and CXCR4 contributes to tumor proliferation, distant metastases, and worsening prognosis. Antagonists and imaging agents targeting CXCL12/CXCR4 have been developed to interfere with and monitor tumor metastasis.

CANCER BIOLOGY & MEDICINE (2021)

Add to Collection

Article Cell Biology

CXCR4-CXCL12-CXCR7 and PD-1/PD-L1 in Pancreatic Cancer: CXCL12 Predicts Survival of Radically Resected Patients

Crescenzo D'Alterio, Alessandro Giardino, Giosue Scognamiglio, Giovanni Butturini, Luigi Portella, Giuseppe Guardascione, Isabella Frigerio, Marco Montella, Stefano Gobbo, Guido Martignoni, Vincenzo Napolitano, Ferdinando De Vita, Fabiana Tatangelo, Renato Franco, Stefania Scala

Summary: CXCR4-CXCL12 evaluation in PDAC identifies prognostic categories and could guide therapeutic approaches.

CELLS (2022)

Add to Collection

Review Oncology

Colorectal Cancer: The Contribution of CXCL12 and Its Receptors CXCR4 and CXCR7

Aissata Aimee Goita, Dominique Guenot

Summary: This review discusses the role of the CXCL12 axis and its receptors CXCR4 and CXCR7 in colorectal cancer, highlighting their potential as therapeutic targets.

CANCERS (2022)

Add to Collection

Article Oncology

Biological Role of Tumor/Stromal CXCR4-CXCL12-CXCR7 in MITO16A/MaNGO-OV2 Advanced Ovarian Cancer Patients

Crescenzo D'Alterio, Anna Spina, Laura Arenare, Paolo Chiodini, Maria Napolitano, Francesca Galdiero, Luigi Portella, Vittorio Simeon, Simona Signoriello, Francesco Raspagliesi, Domenica Lorusso, Carmela Pisano, Nicoletta Colombo, Gian Franco Zannoni, Nunzia Simona Losito, Rossella De Cecio, Giosue Scognamiglio, Daniela Califano, Daniela Russo, Valentina Tuninetti, Maria Carmela Piccirillo, Piera Gargiulo, Francesco Perrone, Sandro Pignata, Stefania Scala

Summary: Despite advances in research on epithelial ovarian cancer, this study systematically evaluated the CXCR4-CXCL12-CXCR7 axis in tumor and stromal cells, identifying a potential prognostic and therapeutic target in high CXCL12 expression in cancer cells. The study highlights the importance of further investigating the CXCL12 axis to improve treatment efficacy in EOC patients.

CANCERS (2022)

Add to Collection

Article Oncology

Interferon regulatory factor 1(IRF-1) activates anti-tumor immunity via CXCL10/CXCR3 axis in hepatocellular carcinoma (HCC)

Yihe Yan, Leting Zheng, Qiang Du, Hamza Yazdani, Kun Dong, Yarong Guo, David A. Geller

Summary: IRF-1 regulates anti-tumor immunity in HCC by modulating CXCL10 and CXCR3, inhibiting proliferation and promoting apoptosis. It overcomes proliferation partly through activating the CXCL10/CXCR3 autocrine axis.

CANCER LETTERS (2021)

Add to Collection

Article Oncology

Control of PD-L1 expression in CLL-cells by stromal triggering of the Notch-c-Myc-EZH2 oncogenic signaling axis

Martin Boettcher, Heiko Bruns, Simon Voelkl, Junyan Lu, Elisavet Chartomatsidou, Nikos Papakonstantinou, Kristin Mentz, Maike Buettner-Herold, Thorsten Zenz, Marco Herling, Wolfgang Huber, Paolo Ghia, Kostas Stamatopoulos, Andreas Mackensen, Dimitrios Mougiakakos

Summary: Chronic lymphocytic leukemia (CLL) cells efficiently evade immunosurveillance through close interaction with stromal niches in the bone marrow and lymph nodes. Enhanced PD-L1 expression on CLL cells following stromal contact contributes to immune escape, controlled by a Notch-c-Myc-EZH2 signaling axis. Elevated PD-L1 levels confer resistance towards activated autologous T-cells, highlighting potential therapeutic targets for improving immune responses in CLL patients.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2021)

Add to Collection

Review Immunology

The chemokines CXCL8 and CXCL12: molecular and functional properties, role in disease and efforts towards pharmacological intervention

Seppe Cambier, Mieke Gouwy, Paul Proost

Summary: Chemokines play a crucial role in regulating leukocyte migration and activation in the immune system. CXCL8 is a potent chemokine that attracts neutrophils and is important in the response to infection and tissue injury. Its activity is dependent on interactions with specific chemokine receptors and glycosaminoglycans. Understanding the structure and regulation of CXCL8 is important for therapeutic development and managing inflammatory diseases and cancer.

CELLULAR & MOLECULAR IMMUNOLOGY (2023)

Add to Collection

Article Dermatology

Cancer-Associated Fibroblasts in Mycosis Fungoides Promote Tumor Cell Migration and Drug Resistance through CXCL12/CXCR4

Anna Aronovich, Lilach Moyal, Batia Gorovitz, Iris Amitay-Laish, Hadas Prag Naveh, Yaara Forer, Lea Maron, Jamal Knaneh, Dean Ad-El, Dafna Yaacobi, Eric Barel, Neta Erez, Emmilia Hodak

Summary: In mycosis fungoides (MF), cancer-associated fibroblasts (CAFs) exhibit higher proliferative capacity than normal skin fibroblasts and protect MF cells from doxorubicin-induced cell death and enhance migration through secretion of CXCL12. Reversing the CAF-mediated tumor microenvironment in MF may improve the efficacy of anticancer therapy.

JOURNAL OF INVESTIGATIVE DERMATOLOGY (2021)

Add to Collection

Article Immunology

Sphingomyelin Depletion Inhibits CXCR4 Dynamics and CXCL12-Mediated Directed Cell Migration in Human T Cells

Sofia R. Gardeta, Eva M. Garcia-Cuesta, Gianluca D'Agostino, Blanca Soler Palacios, Adriana Quijada-Freire, Pilar Lucas, Jorge Bernardino de la Serna, Carolina Gonzalez-Riano, Coral Barbas, Jose Miguel Rodriguez-Frade, Mario Mellado

Summary: The local lipid environment plays an important role in regulating CXCR4 organization and function, and modulating chemokine-triggered directed cell migration. Treatment of T cells with bacterial sphingomyelinase alters the lipid composition of the cell membrane, affecting membrane fluidity and CXCR4 nanoclustering and dynamics.

FRONTIERS IN IMMUNOLOGY (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Macrophage polarization by MSC-derived CXCL12 determines tumor growth

Shabnam Babazadeh, Seyed Mahdi Nassiri, Vahid Siavashi, Mohadeseh Sahlabadi, Mostafa Hajinasrollah, Mohamad Zamani-Ahmadmahmudi

Summary: The study reveals the impact of MSC-derived CXCL12 on macrophage phenotypic switching towards M2, influencing their function in tumorigenesis.

CELLULAR & MOLECULAR BIOLOGY LETTERS (2021)

Add to Collection

Article Oncology

Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study

Kevin J. Harrington, Barbara Burtness, Richard Greil, Denis Soulieres, Makoto Tahara, Gilberto de Castro Jr, Amanda Psyrri, Irene Brana, Neus Baste, Prakash Neupane, Ase Bratland, Thorsten Fuereder, Brett G. M. Hughes, Ricard Mesia, Nuttapong Ngamphaiboon, Tamara Rordorf, Wan Zamaniah Wan Ishak, Jianxin Lin, Burak Gumuscu, Ramona F. Swaby, Danny Rischin

Summary: The study presents a post hoc analysis of the long-term efficacy and progression-free survival in recurrent/metastatic head and neck squamous cell carcinoma patients treated with pembrolizumab and pembrolizumab-chemotherapy as next-line therapy. The results demonstrate favorable clinical efficacy and progression-free survival with pembrolizumab and pembrolizumab-chemotherapy in patients with programmed death ligand 1 (PD-L1) combined positive score (CPS) >= 20, CPS >= 1, and total populations. Subsequent treatments after pembrolizumab-based therapy also showed good efficacy.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Does the number of 6-monthly adjuvant zoledronate infusions received affect treatment efficacy for early breast cancer? A sub-study of ABCSG-12

Ana-Alicia Beltran-Bless, Mark J. Clemons, Christian Fesl, Richard Greil, Gregory R. Pond, Marija Balic, Lisa Vandermeer, Vesna Bjelic-Radisic, Christian F. Singer, Guenther G. Steger, Ruth Helfgott, Daniel Egle, Lidija Soelkner, Simon P. Gampenrieder, Stephanie Kacerovsky-Strobl, Christoph Suppan, Magdalena Ritter, Gabriel Rinnerthaler, Georg Pfeiler, Hannes Fohler, Dominik Hlauschek, John Hilton, Michael Gnant

Summary: The impact of early treatment cessation on adjuvant bisphosphonate therapy for postmenopausal early breast cancer patients was evaluated. The study found that the number of bisphosphonate infusions had no significant association with breast cancer-specific outcomes. Further research is needed to define optimal regimens of adjuvant bone-targeted therapies.

EUROPEAN JOURNAL OF CANCER (2023)

Add to Collection

Article Oncology

Influence of HER2 expression on prognosis in metastatic triple-negative breast cancerdresults from an international, multicenter analysis coordinated by the AGMT Study Group

S. P. Gampenrieder, V. Dezentje, M. Lambertini, A. de Nonneville, M. Marhold, F. Le Du, A. Cortes Salgado, D. Alpuim Costa, M. Vaz Batista, N. Chic Ruche, C. Tinchon, A. Petzer, E. Blondeaux, L. Del Mastro, G. Targato, F. Bertucci, A. Goncalves, F. Viret, R. Bartsch, C. Mannsbart, A. Deleuze, L. Robert, C. Saavedra Serrano, M. Gion Cortes, M. Sampaio-Alves, M. Vitorino, L. Pecen, C. Singer, N. Harbeck, G. Rinnerthaler, R. Greil

Summary: Based on a large international dataset of metastatic TNBC, the frequency of HER2-low was 32.0%, but it showed no significant impact on overall survival (OS).

ESMO OPEN (2023)

Add to Collection

Review Oncology

How I treat diffuse large B-cell lymphoma

T. Melchardt, A. Egle, R. Greil

ESMO OPEN (2023)

Add to Collection

Article Oncology

Barriers to patient access of CAR T cell therapies in Austria

Georg Hopfinger, Bernhard Rupp, Richard Greil

Summary: Chimeric antigen receptor (CAR) T cell therapies have the potential to be an effective treatment option for B cell malignancies, particularly relapsed or refractory diffuse large B cell lymphoma (DLBCL). However, despite being available in wealthy Western countries, patient access to CAR-T therapy can be limited due to systemic barriers. In Austria, a significant percentage of eligible DLBCL patients did not receive CAR-T therapy in 2021, raising concerns about accessibility. This report identifies barriers to access and provides recommendations for systemic solutions to improve CAR-T access in Austria.

MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma

Andrea Keppler-Hafkemeyer, Christine Greil, Paul R. Wratil, Khalid Shoumariyeh, Marcel Stern, Annika Hafkemeyer, Driti Ashok, Alexandra Hollaus, Gaia Lupoli, Alina Priller, Marie L. Bischof, Gabriele Ihorst, Monika Engelhardt, Reinhard Marks, Juergen Finke, Hannah Bertrand, Christopher Daechert, Maximilian Muenchhoff, Irina Badell, Florian Emmerich, Hridi Halder, Patricia M. Spaeth, Percy A. Knolle, Ulrike Protzer, Michael Von Bergwelt-Baildon, Justus Duyster, Tanja N. Hartmann, Andreas Moosmann, Oliver T. Keppler

Summary: This observational study analyzed the immune response to COVID-19 vaccination in individuals with hematologic malignancies, specifically B cell lymphomas and multiple myeloma. Despite lower levels of antibodies, these individuals showed rapid development of potent infection neutralization capacities against different variants of concern. Additionally, robust T cell responses were observed, leading to mainly mild to moderate breakthrough infections. The study suggests that COVID-19 vaccination can induce broad antiviral immunity, including ultrapotent neutralizing antibodies, in patients with hematologic malignancies.

NATURE CANCER (2023)

Add to Collection

Article Hematology

RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma

Grzegorz S. Nowakowski, Dok Hyun Yoon, Patrizia Mondello, Erel Joffe, Anthea Peters, Isabelle Fleury, Richard Greil, Matthew Ku, Reinhard Marks, Kibum Kim, Pier Luigi Zinzani, Judith Trotman, Lorenzo Sabatelli, Eva E. Waltl, Mark Winderlich, Andrea Sporchia, Nuwan C. Kurukulasuriya, Raul Cordoba, Georg Hess, Gilles Salles

Summary: The RE-MIND2 study compared the patient outcomes of tafasitamab+lenalidomide with other therapies for relapsed/refractory DLBCL. The data showed that tafasitamab+lenalidomide had better overall survival rates compared to polatuzumab vedotin+bendamustine+rituximab and rituximab+lenalidomide.

ANNALS OF HEMATOLOGY (2023)

Add to Collection

Article Oncology

Real-world Data of Palliative First-line Checkpoint Inhibitor Therapy for Head and Neck Cancer

Sandro. M. Wagner, Teresa Magnes, Thomas Melchardt, Dominik Kiem, Lukas Weiss, Daniel Neureiter, Christina Wagner, Marie-Bernadette Aretin, Stefan Nemec, Gabriele Gamerith, Georg Pall, Richard Greil, Thorsten Fuereder

Summary: This study evaluated the efficacy and safety of immune checkpoint inhibitor therapy in unselected patients with SCCHN. The results showed that CPI therapy alone or in combination with chemotherapy is an effective treatment for SCCHN patients, consistent with previous studies.

ANTICANCER RESEARCH (2023)

Add to Collection

Article Biochemical Research Methods

Validation of genetic variants from NGS data using deep convolutional neural networks

Marc Vaisband, Maria Schubert, Franz Josef Gassner, Roland Geisberger, Richard Greil, Nadja Zaborsky, Jan Hasenauer

Summary: Accurate somatic variant calling from next-generation sequencing data is crucial for personalised cancer therapy. A machine learning approach using a Convolutional Neural Network can improve the validation of genetic variants, incorporating contextual data from sequencing tracks. This model performs on par with trained researchers and enhances reproducibility and scalability.

BMC BIOINFORMATICS (2023)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Prognostic value of [18F]FDG PET/CT on treatment response and progression-free survival of gastroesophageal cancer patients undergoing perioperative FLOT chemotherapy

Seyed Ali Mirshahvalad, Seyedeh Sara Seyedinia, Florian Huemer, Gregor Schweighofer-Zwink, Oliver Koch, Wolfgang Hitzl, Lukas Weiss, Klaus Emannuel, Richard Greil, Christian Pirich, Mohsen Beheshti

Summary: The purpose of this study was to evaluate the prognostic role of [18F]FDG PET/CT metabolic parameters in gastric cancer and gastroesophageal adenocarcinoma patients receiving neoadjuvant chemotherapy. The results showed that pre-neoadjuvant chemotherapy SULpeak was significantly correlated with pathological response to treatment and post-chemotherapy metabolic parameters were significantly correlated with progression-free survival. Therefore, performing [18F]FDG PET/CT before chemotherapy may help identify patients at risk for inadequate response to perioperative FLOT and predict clinical outcomes after chemotherapy.

EUROPEAN JOURNAL OF RADIOLOGY (2023)

Add to Collection

Letter Oncology

Prognostic value of extracellular matrix gene mutations and expression in multiple myeloma

Marietheres Evers, Martin Schreder, Thorsten Stuehmer, Franziska Jundt, Regina Ebert, Tanja Nicole Hartmann, Michael Altenbuchinger, Martina Rudelius, Martin Kuric, Wyonna Darleen Rindt, Torsten Steinbrunn, Christian Langer, Sofia Catalina Heredia-Guerrero, Hermann Einsele, Ralf Christian Bargou, Andreas Rosenwald, Ellen Leich

BLOOD CANCER JOURNAL (2023)

Add to Collection

Correction Hematology

RE-MIND2: comparative effectiveness of tafasitamab plus lenalidomide versus polatuzumab vedotin/bendamustine/rituximab (pola-BR), CAR-T therapies, and lenalidomide/rituximab (R2) based on real-world data in patients with relapsed/refractory diffuse large B-cell lymphoma (vol 102, pg 1773, 2023)

Grzegorz S. Nowakowski, Dok Hyun Yoon, Patrizia Mondello, Erel Joffe, Anthea Peters, Isabelle Fleury, Richard Greil, Matthew Ku, Reinhard Marks, Kibum Kim, Pier Luigi Zinzani, Judith Trotman, Lorenzo Sabatelli, Eva E. Waltl, Mark Winderlich, Andrea Sporchia, Nuwan C. Kurukulasuriya, Raul Cordoba, Georg Hess, Gilles Salles

ANNALS OF HEMATOLOGY (2023)

Add to Collection

Meeting Abstract Oncology

Management of metastatic colorectal cancer in patients >= 70 years: A single-center experience

F. Huemer, C. Dunkl, G. Rinnerthaler, K. Schlick, R. Heregger, K. Emmanuel, D. Neureiter, E. Klieser, M. Deutschmann, F. Roeder, R. Greil, L. Weiss

ANNALS OF ONCOLOGY (2023)

Add to Collection

Article Biochemical Research Methods

NanoB2 to monitor interactions of ligands with membrane proteins by combining nanobodies and NanoBRET

Jelle van den Bor, Nick D. Bergkamp, Stephanie M. Anbuhl, Francoise Dekker, Dehan Comez, Claudia V. Perez Almeria, Reggie Bosma, Carl W. White, Laura E. Kilpatrick, Stephen J. Hill, Marco Siderius, Martine J. Smit, Raimond Heukers

Summary: The use of nanobodies and NanoBRET methods allows for real-time monitoring of nanobody-receptor binding, predicting the therapeutic potential of ligands targeting disease-associated membrane proteins, which is significant for drug research.

CELL REPORTS METHODS (2023)

Add to Collection

Letter Oncology

Molecular characterization of the CXCR4 / CXCR7 axis in germ cell tumors and its targetability using nanobody-drug-conjugates

Gamal A. Wakileh, Philipp Bierholz, Mara Kotthoff, Margaretha A. Skowron, Felix Bremmer, Alexa Stephan, Stephanie M. Anbuhl, Raimond Heukers, Martine J. Smit, Philipp Stroebel, Daniel Nettersheim

Summary: This study identified a nanobody-drug-conjugate targeting CXCR4 as a potential therapeutic option for GCT. Furthermore, this study shed light on the functional role of the CXCR4 / CXCR7 / CXCL12-signaling cascade in GCT, demonstrating an important influence on proliferation and migration.

EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2023)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.